Alexandre Mebazaa
Alexandre Mebazaa is an expert in Cardiology at Hôpital Lariboisière (France). As of October 2026, ScienceLeadR ranks Alexandre Mebazaa in the top 1% of experts worldwide for Heart Failure, Renal Insufficiency and Intensive Care Units. Alexandre Mebazaa has authored 1,150 publications, the most recent in 2026, and is an investigator in 49 clinical trials, 5 of them ongoing. SLR score: 4,822 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Critical Care - Public Health - Anesthesiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1989 - 2026
Number : 1150
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Acute heart failure in emergency settings. PMID 42906949 — emergencies, heart failure, heart, cardiology, biomarkers, therapeutics, emergency medical services | Eur Heart J Top journal | 2026 | 0 |
| Early postoperative galectin-3 for risk stratification of delayed graft function after kidney transplantation. PMID 42871982 — galectins, risk assessment, galectin 3, kidney, delayed graft function, biomarkers, transplants, intensive care units, kidney transplantation, transplantation | Clin Kidney J | 2026 | 0 |
| GDMT is Associated with Reduced Loop Diuretic Requirements, Whereas Diuretic Dose Does Not Modify GDMT Benefit in Heart Failure: STRONG-HF. PMID 42852467 — heart failure, heart, diuretics, therapeutics, furosemide, prognosis | Eur J Heart Fail | 2026 | 0 |
| Plasma proteomics defines two reproducible subphenotypes of sepsis-associated acute kidney injury with distinct outcomes. PMID 42844256 — kidney, sepsis, proteomics, therapeutics, acute kidney injury, plasma | Nat Commun | 2026 | 0 |
| Precipitants of Acute Heart Failure: A State-of-the-art Review from an International Expert Group. PMID 42741576 — epidemiology, heart failure, heart, therapeutics | Card Fail Rev | 2026 | 0 |
Clinical Studies 49
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 14
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Dapagliflozin for Cardio renal Protection After ICU Discharge NCT07025629 — kidney diseases, sodium-glucose transporter 2 inhibitors, heart failure, heart, recycling, tablets, kidney, biomarkers, critical illness, intensive care units, random allocation, cardio-renal syndrome | Phase 3 | Recruiting | 2025 |
| A Phase 1b 2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ AK1967) in Critical Cardiovascular Care NCT06832722 — safety, shock, cardiogenic, multiple chronic conditions, peptide hydrolases, antibodies, monoclonal, pharmacokinetics | Phase 1/Phase 2 | Recruiting | 2025 |
| Shock and Acute Conditions OutcOmes Platform NCT06376318 — adrenomedullin, antibodies, shock, cardiogenic, norepinephrine, extracorporeal membrane oxygenation, shock, surgical, hospital mortality, critical care, biomarkers, milrinone, machine learning, epinephrine, dobutamine, sepsis, peptide hydrolases, therapeutics, intensive care units, learning, wounds and injuries, membranes, mechanical circulatory support | N/A | Active not recruiting | 2024 |
| Registry Of Best Up titration STrategies in Acute Heart Failure NCT05865665 — registries, disease management, heart failure, heart, biomarkers, angiotensins, medication therapy management, therapeutics | N/A | Not yet recruiting | 2023 |
| Addiction in Intensive Cardiac Care Units NCT05063097 — dronabinol, antidepressive agents, research design, buprenorphine, heart diseases, n-methyl-3,4-methylenedioxyamphetamine, heroin, hospitalization, cocaine, methadone, pharmaceutical preparations, benzodiazepines, heart, substance-related disorders, psychotropic drugs, prevalence, tobacco use, intensive care units, barbiturates, amphetamines, smoking, cannabinoids, antidepressive agents, tricyclic, illicit drugs | N/A | Active not recruiting | 2021 |
LeadR Networks
Main global connection map